

Regenerating The Male Foreskin Through Tissue Engineering

Introduction Slides - 2022

Research Shows That Circumcision Can Cause Significant

Physical And Psychological Harm.



Foregen's Goal Is To Offer Men A Solution They Have Hoped For, And Deserve,

By Regenerating The Entire Foreskin.



The history and the founding

Foregen is a 501(c)(3) non-profit organization **founded in 2010** to research and implement regenerative medical therapies for circumcised men.

We recruited talented scientists and began the initial experiments in 2014. Foregen now **operates in both the United States and the European Union.**

We are headed by a board of directors with staff, leadership and donors from **over 80 countries across 6 continents.**



To date, we have received over \$1.3 million in donations. We are the only organization in the world with this mission.

Leadership



Vincenzo Aiello President

World-renowned for restoring ancient Roman mosaics and creating new ones, contemporary artist Vincenzo founded Foregen in 2010.

Carlo Alberto Cirioni Vice President

As a philosopher and anthropologist, Carlo is a religious scholar and interpreter of ancient Biblical texts.

He helps lead the creative direction of Foregen, and is a visionary in his own right.



Eric J. Cunningham Chief Science Officer

Eric holds a Bachelor's in Biomedical Engineering, with a specialization in Cell & Tissue Engineering, and a Master's of Chemical Engineering from Illinois Institute of Technology.



Tyler J. Drozd Chief Operations Officer

Tyler has considerable international experience, including as a Fulbright Scholar to Germany, and is now pursuing an MBA at FOM University of Applied Sciences for Economics and Management.

Scientists



Elena Bondioli, Ph.D. Technical Director

Dr. Bondioli is Foregen's chief molecular biologist responsible for overseeing Foregen's lab work.

She has 10+ years of experience with the fundamental scientific process that Foregen's success depends on.



Valeria Purpura, Ph.D. Lead Biotechnologist

Dr. Purpura was a senior diagnostic molecular biologist at Praximedica before becoming Dr. Bondioli's head biotechnologist.

She received her Ph.D. in experimental medicine in 2012.



Angela Palumbo Piccionello, Ph.D., D.V.M. Lead Veterinary Scientist

Dr. Palumbo is Foregen's veterinary scientist and supervisor of Foregen's Animal Trials.

She is a Professor of Surgery and Anesthesiology at the University of Camerino's School of Biosciences and Veterinary Medicine.

She holds both a Doctor of Veterinary Medicine degree as well as a Ph.D. in Animal Orthopedics.

Staff





Matthew Serody Senior Director, Administration

Oscar Perez Director, Digital Development & IT



Mason Michalec Senior Associate, Digital Development & IT



Ryan Jones Communications Officer, Operations

Advisers



Peter Adler J.D., M.A. Legal Adviser



Robert Van Howe M.D. Medical Adviser



William Musa M.S. Research Adviser



Elena Steiner Ph.D. Communication Adviser



Adam Lavine Executive Adviser



Shingo Lavine

Executive Adviser

The problem

Circumcision is the most common surgery in the world, yet most often unnecessary. While it is a controversial practice, it does cause serious harms.

These include:

- Lack of control over one's body
- Reduced sensitivity
- Wide range of potential complications
- Psychological trauma

Men all over the world have spoken up about the damaging effects they have experienced, and we are here to offer them a permanent solution.

The solution

Sexual Sensitivity

Having a foreskin can increase pleasure during sexual activity.

Natural Function

The foreskin will restore the function of the penis as nature intended.

Psychological Well-being

Have peace of mind knowing that your integrity as a man has been restored.

Genital Integrity

Reclaim your whole body by supporting the work of foreskin regeneration.





The aim of Foregen's research is to regenerate the foreskin via tissue engineering techniques, and thereby restore its biological functions and benefits.

To date, this research has consisted of preliminary tests on animal foreskin tissue to prove our decellularization method, and successful testing of this method on human foreskin tissue. This was followed by the animal trial phase, which is in progress, to examine aspects like biocompatibility and vascularization of the decellularized tissue. A critical component of the overall effort are two ongoing histological studies, one with HistologiX, a UK-based biotech research company, and the other with Dr. Giacomo Pagliaro at the University of Camerino.





The final experiments -

the human clinical trial - is scheduled to begin in April 2023.

Previous research and accomplishments

Preliminary Phase

Stage 1 - Acquire qualified scientists with properly equipped laboratories for research

Stage 2 - Conduct preliminary experiments on animal tissue to prove a viable method

for decellularization

Stage 3 - Report results of preliminary research on animal tissue in scholarly article

Phase 1

Stage 1 - Acquire regulatory approval as well as human tissue for decellularization

Stage 2 - Conduct experiments on human tissue to prove efficacy of decellularization technique

Stage 3 - Publish the results of human foreskin tissue decellularization in peer-reviewed article

Where we are at

Future research and entering the market

Phase 3



Phase 2

conduct a two part animal trial

Stage 1 - Acquire tissue necessary to

Stage 2 - Obtain ethics committee approval for Phase II

Stage 3 - In Progress - Conduct two part animal trial and publish results



Stage 1 - Receive ethics committee and

- regulatory body approval for human clinical trials
 - Stage 2 Conduct the approved human
 - clinical trial
 - **Stage 3 -** Organize and subsequently release the procedure to the public

Market size

106.2 Million

Number of circumcised men by main target market countries. (Across the U.S., U.K., South Korea, Canada, and Australia)



Cultural shifts will lead to more men who desire a reversal





5 Million (YouGov Survey from 2021)

Traction

Raised over \$600,000 from donors in 2021

Current **recurring donor** base of over 500 people provides around **\$13,500 per month**



First paper published in 2018 on

decellularization with patents held by Foregen's lead scientists

Work currently underway in sheep phase of animal trials after **successful conclusion of rat model**

Human trials scheduled to follow in April 2023

Lead surgeon has begun **developing** the surgical protocols and refining techniques on cadavers

Regain Full Functionality Thank You!



North America

55 E. Monroe St. Suite 3800 Chicago, Illinois 60603 United States

European Union

Via Campi Flegrei 59 00141 Rome, Italy